Insights Into the Inhibition of MOX-1 β-Lactamase by S02030, a Boronic Acid Transition State Inhibitor

The rise of multidrug resistant (MDR) Gram-negative bacteria has accelerated the development of novel inhibitors of class A and C beta-lactamases. Presently, the search for novel compounds with new mechanisms of action is a clinical and scientific priority. To this end, we determined the 2.13-angstrom resolution crystal structure of S02030, a boronic acid transition state inhibitor (BATSI), bound to MOX-1 beta-lactamase, a plasmid-borne, expanded-spectrum AmpC beta-lactamase (ESAC) and compared this to the previously reported aztreonam (ATM)-bound MOX-1 structure. Superposition of these two complexes shows that S02030 binds in the active-site cavity more deeply than ATM. In contrast, the SO3 interactions and the positional change of the beta-strand amino acids from Lys315 to Asn320 were more prominent in the ATM-bound structure. MICs were performed using a fixed concentration of S02030 (4 mu g/ml) as a proof of principle. Microbiological evaluation against a laboratory strain of Escherichia coli expressing MOX-1 revealed that MICs against ceftazidime are reduced from 2.0 to 0.12 mu g/ml when S02030 is added at a concentration of 4 mu g/ml. The IC50 and K-i of S02030 vs. MOX-1 were 1.25 +/- 0.34 and 0.56 +/- 0.03 mu M, respectively. Monobactams such as ATM can serve as informative templates for design of mechanism-based inhibitors such as S02030 against ESAC beta-lactamases.

Automated summary

The study identified a novel boronic acid transition state inhibitor S02030 that can effectively inhibit multidrug-resistant Gram-negative bacteria, providing a potential new direction for future treatments.